Planview Completes Acquisitions of Clarizen and Changepoint
Planview, a global leader in Portfolio Management and Work Management solutions, today announced it has closed its previously announced acquisitions of Clarizen and Changepoint, two leading Project Portfolio Management (PPM) providers.
“For more than three decades, Planview has been pioneering the technologies and best practices that the world’s best companies use to reimagine the ways they plan and manage work,” said Greg Gilmore, CEO of Planview. “Together, Planview, Clarizen, and Changepoint offer a portfolio for the modern enterprise, providing organizations the visibility and agility needed to drive more innovation, execute on their strategic objectives, and capitalize on compelling opportunities. We are thrilled to welcome Clarizen and Changepoint into the extended Planview family.”
As a result of the transaction, Planview, Clarizen and Changepoint customers will benefit from being part of a premier community of PMOs, PPM, and Professional Services Automation (PSA) practitioners. The expanded portfolio of solutions will provide customers the tools and resources to better strategically plan and deliver on their most important initiatives. The combination will be transformative for the industry and has received strong feedback from customers to date.
The nature of work has changed significantly in recent years, causing leaders across industries to rethink how to best strategically plan, execute, and empower teams in today’s all-digital world. This shift has placed a spotlight on the growing importance and strategic value of Portfolio Management, Work Management and Enterprise Agile Planning capabilities, as evidenced by the recent wave of IPOs, consolidation, and acquisitions of several key players in this category. Planview’s rich history in the space, acquisitions of Clarizen and Changepoint, its comprehensive product offerings, and its significant growth position have placed the company at the forefront of this global market.
“This acceleration of PPM and work management acquisitions indicates the vital need for companies to adapt and manage the way they work in the face of fast changes to the global economy and competitive landscapes,” said Melinda Ballou, Research Director, Agile ALM, Quality & Portfolio Strategies at IDC. “The need to respond adaptively and collaboratively to unexpected change will endure. This dual acquisition on the part of Planview is a bold move to scale the company in several related and growing market areas, and with effective integration and alignment, we would expect more strategic positioning for Planview moving forward.”
The close of the transactions closely follows Planview’s acquisition in December 2020 by TPG Capital and TA Associates, whose investment has focused on accelerating Planview’s growth and vision for Agile and PPM for Enterprises. Clarizen and Changepoint are the company’s largest acquisitions to date and represent an important first step in Planview’s growth strategy for 2021.
Planview is also coming off of its strongest financial year in company history, capped by a fourth quarter that included its largest customer deal and most successful financial quarter on record, as well as a significant uptick in customer adoption of Planview’s Lean and Agile Delivery solutions. To learn more, visit: www.planview.com.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: the Planview website at www.planview.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005335/en/
Contact information
Planview
Leslie Marcotte
719-439-4921
lmarcotte@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MarkLines Gen-AI Beta Version Released for Automotive Industry13.1.2026 02:00:00 EET | Press release
MarkLines Co., Ltd. (Headquarters: Minato-ku, Tokyo; President & CEO: Makoto Sakai; TYO:3901) announced its launch of the "MarkLines Gen-AI Beta Version," the new feature for B2B users in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112383839/en/ "MarkLines Gen-AI Beta Version" can take questions in natural language and instantly give highly reliable, relevant data drawn from MarkLines’ extensive automotive database (Image: MarkLines Co., Ltd.) This AI-powered feature enables users to ask questions in natural language and instantly receive highly reliable, relevant data drawn from MarkLines’ extensive automotive database. Moreover, the system analyzes this information by leveraging the rich content across its platform and delivers clear, concise, text-based insights. By combining trusted data with advanced analytical capabilities through generative AI, this service represents a first-of-its-kind
Australian Defence Force Secures Satellite Communications on SES IS-2212.1.2026 23:30:00 EET | Press release
Satellite communications solutions provider SES will provide secure uninterrupted satellite communications to the Australian Defence Force (ADF) for a minimum of 16 years thanks to a new extended agreement. The service will be provided via the SES Intelsat 22 satellite and an ultra-high frequency (UHF) military communications payload. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112137182/en/ Assistant Secretary Space Systems Branch, Michael Hunt, formalizes contract negotiations for the through-life support of the IS-22 satellite with Rory Welch, senior vice-president of service delivery at SES Space and Defense. Photos: Corporal Annika Smit Under the renewed arrangement, SES will reposition the IS-22 satellite to a new orbital slot specified by the ADF, continuing a mission that has been the cornerstone of Australia’s secure military communications since IS-22’s launch in 2012. SES will build a dedicated ground segmen
NetApp Appoints Paul Fipps to the Board of Directors12.1.2026 23:05:00 EET | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that Paul Fipps, President of Global Customer Operations at ServiceNow, has joined its Board of Directors. The board now has ten directors, nine of whom are independent, and 50% of whom have been appointed within the last five years. Fipps brings more than 20 years of experience driving technology-enabled growth and customer transformation. At ServiceNow, he currently leads global sales, customer success, partner ecosystems, and field operations. He previously served as EVP of Worldwide Sales at ServiceNow and as President of Under Armour Connected Fitness and Chief Experience Officer at Under Armour, overseeing global direct-to-consumer, connected fitness, and digital experiences. He also previously served on the advisory board of Quantum Metric. Fipps holds a B.S. in Information Systems, an MBA from the University of Baltimore, and is a graduate of The Wharton School’s Advanced Management Program. “P
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor12.1.2026 21:00:00 EET | Press release
Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s new drug application (NDA) for pimicotinib as a systemic treatment for patients with tenosynovial giant cell tumor (TGCT). The application is based on the primary results and longer-term follow-up of the global Phase 3 MANEUVER study, which demonstrated deep and durable tumor responses and meaningful improvements in clinical outcomes with pimicotinib. “With pimicotinib, we have an opportunity to significantly advance care for people living with TGCT, a painful and debilitating disease that has few effective and well-tolerated treatment options beyond surgery,” said David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “Based on clinical trial results showing not only a reduction in tumor burden, but also the ability to help alleviate symptoms like pain and stiffness in the global Phase 3 MANEUVER study
Fabentech receives Marketing Authorization for Ricimed®, an antidote against ricin poisoning12.1.2026 20:32:00 EET | Press release
Fabentech, a French biopharmaceutical company specializing in medical countermeasures against biological threats, today announces that it has been granted Marketing Authorization for Ricimed®, a treatment for ricin poisoning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112241557/en/ Ricimed - Fabentech Ricimed®, an antidote against one of the most toxic natural substances in the world In addition to supportive care, and in severe situations requiring immediate administration, Ricimed® represents a new therapeutic option for the management of acute ricin intoxication. Ricin, among the most dangerous naturally occurring substances, can cause death within hours or days regardless of the route of exposure, making it a major biological threat for many countries. Having demonstrated its ability to specifically target and neutralize ricin before irreversible damage occurs, Ricimed® is an antibody-based therapy relying on poly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom